The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis.
CONCLUSIONS: These findings support the use of agonistic TRAIL antibodies and drugs targeting FLIP in breast cancer patients. Over-expression of FLIPT but not TRAIL-R1, TRAIL-R2 or FLIPL provides stage-independent prognostic information in breast cancer patients. This indicates a clinically less aggressive phenotype. PMID: 25230899 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 18, 2014 Category: Cancer & Oncology Authors: Ullenhag GJ, Al-Attar A, Mukherjee A, Green AR, Ellis IO, Durrant LG Tags: J Cancer Res Clin Oncol Source Type: research

Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models.
Abstract Purpose: Tumor cells are surrounded by a complex microenvironment. The purpose of our study was to evaluate the role of heterogeneity of the tumor microenvironment in the variability of nanoparticle (NP) delivery and efficacy. Experimental Design: C3(1)-T-Antigen genetically engineered mouse model (C3-TAg) and T11/TP53Null orthotopic syngeneic murine transplant model (T11) representing human breast tumor subtypes basal-like and claudin-low, respectively, were evaluated. For the pharmacokinetic studies, non-liposomal doxorubicin (NL-doxo) or polyethylene glycol tagged (PEGylated) liposomal doxorubicin (PLD...
Source: Clinical Breast Cancer - September 17, 2014 Category: Cancer & Oncology Authors: Song G, Darr D, Santos CM, Ross M, Valdivia A, Jordan J, Midkiff BR, Cohen SM, Feinberg NN, Miller CR, Tarrant TK, Rogers AB, Dudley AC, Perou CM, Zamboni WC Tags: Clin Cancer Res Source Type: research

First-in-Human study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics and Pharmacodynamics, in Patients with Metastatic Cancer.
Conclusion: CH5132799 is well tolerated at the MTD dose 48 mg BID. At this dose the drug had a favorable PK and PD profile and preliminary evidence of clinical activity. PMID: 25231405 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 17, 2014 Category: Cancer & Oncology Authors: Blagden S, Omlin A, Josephs DH, Stavraka C, Zivi A, Pinato DJ, Anthoney DA, Decordova S, Swales K, Riisnaes R, Pope L, Noguchi K, Shiokawa R, Inatani M, Prince J, Jones K, Twelves CJ, Spicer JF, Banerji U Tags: Clin Cancer Res Source Type: research

Human epidermal growth factor receptor 2 testing in gastric cancer: Recommendations of an Asia-Pacific Task Force.
Abstract Human epidermal growth factor receptor 2 (HER2) testing in gastric and gastroesophageal junction cancer is an evolving area in clinical practice that has particular relevance to Asia-Pacific countries, which face a high incidence of these diseases. A growing body of evidence demonstrates that HER2-targeted therapy improves survival for patients with HER2-positive advanced disease, and drives the need for high-quality testing procedures to identify patients who will respond to treatment. However, various factors challenge day-to-day testing of gastric specimens in these countries, to a degree greater than ...
Source: Clinical Breast Cancer - September 16, 2014 Category: Cancer & Oncology Authors: Kim KM, Bilous M, Chu KM, Kim BS, Kim WH, Park YS, Ryu MH, Sheng W, Wang J, Chao Y, Ying J, Zhang S Tags: Asia Pac J Clin Oncol Source Type: research

Two cases of dermatoses koebnerizing within fields of previous radiotherapy.
We describe two patients with newly diagnosed dermatoses localizing to the radiotherapy field following treatment for breast cancer. Patient 1 was a 53-year-old woman who developed bullous morphoea on her left breast two years after radiotherapy. Patient 2 was a 43-year-old woman who developed urticaria pigmentosa on her right breast eight months after radiotherapy and similar lesions gradually developed beyond the radiotherapy field. Both patients experienced a significant delay in diagnosis due to diagnostic confusion and concern over breast cancer recurrence. Irradiated skin demonstrates gradual and sustained ...
Source: Clinical Breast Cancer - September 15, 2014 Category: Cancer & Oncology Authors: Hellen R, Kiely C, Murad A, Mulligan N, Coffey J, Lenane P, Moloney FJ Tags: Clin Exp Dermatol Source Type: research

Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype.
CONCLUSIONS: SCC with basal-HER2 phenotype is an extremely rare subset of breast carcinoma. Since it may have worse prognosis than typical basal-like SCC, recognization of this unusual SCC in routine work may have obvious clinical significance. PMID: 25197398 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 14, 2014 Category: Cancer & Oncology Authors: Shui R, Li A, Yang F, Zhou X, Yu B, Xu X, Yang W Tags: Int J Clin Exp Pathol Source Type: research

Synchronous uterine carcinosarcoma and contralateral breast cancer after tamoxifen therapy: a case report.
We present a case of uterine carcinosarcoma co-occurrenced with contralateral breast cancer in a 56-year-old nulliparous, obese breast cancer patient, who had been treated with tamoxifen for 5 years. The patient presented with palpable pelvic mass and vaginal bleeding. Histopathological evidence revealed that the tumor was comprised of an admixture of malignant epithelial and mesenchymal components. The epithelial component was endometrioid type adenocarcinoma, while sarcomatous component had heterologous elements including fusiform cell sarcoma and a prominent component of cartilage. The infiltrating ductal carcinoma has ...
Source: Clinical Breast Cancer - September 14, 2014 Category: Cancer & Oncology Authors: Shen L, Hong L, Zhang G, Mai R Tags: Int J Clin Exp Pathol Source Type: research

Selective estrogen receptor modulators: tissue specificity and clinical utility.
Abstract Selective estrogen receptor modulators (SERMs) are a diverse group of nonsteroidal compounds that function as agonists or antagonists for estrogen receptors (ERs) in a target gene-specific and tissue-specific fashion. SERM specificity involves tissue-specific expression of ER subtypes, differential expression of co-regulatory proteins in various tissues, and varying ER conformational changes induced by ligand binding. To date, the major clinical applications of SERMs are their use in the prevention and treatment of breast cancer, the prevention of osteoporosis, and the maintenance of beneficial serum lipi...
Source: Clinical Breast Cancer - September 14, 2014 Category: Cancer & Oncology Authors: Martinkovich S, Shah D, Planey SL, Arnott JA Tags: Clin Interv Aging Source Type: research

Breast Adipose Tissue Estrogen Metabolism in Postmenopausal Women with or without Breast Cancer.
Conclusions: Estrogen metabolism is differently regulated in the adipose tissue of women with or without cancer. In the subcutaneous adipose tissue proximal to breast tumor 17β-hydroxysteroid dehydrogenase type 12 expression is lower than in controls, which could indicate that the conversion of estrone to estradiol is decreased. Further studies are needed to establish the clinical significance of our findings in the development and growth of breast cancer in postmenopausal women. PMID: 25215559 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 12, 2014 Category: Cancer & Oncology Authors: Savolainen-Peltonen H, Vihma V, Leidenius M, Wang F, Turpeinen U, Hämäläinen E, Tikkanen MJ, Mikkola TS Tags: J Clin Endocrinol Metab Source Type: research

Design and validation of an oligonucleotide microarray for the detection of genomic rearrangements associated with common hereditary cancer syndromes.
ConclusionThe use of microarray comparative genomic hybridization (CGH) for the detection of LRs is well-suited as an adjunct technology for both single syndrome (by Sanger sequencing analysis) and extended gene panel testing by next generation sequencing analysis. Genetic testing strategies using microarray analysis will help identify additional patients carrying LRs, who are predisposed to various hereditary cancers. PMID: 25204323 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 11, 2014 Category: Cancer & Oncology Authors: Mancini-DiNardo D, Judkins T, Woolstenhulme N, Burton C, Schoenberger J, Ryder M, Murray A, Gutin N, Theisen A, Holladay J, Craft J, Arnell C, Moyes K, Roa B Tags: J Exp Clin Cancer Res Source Type: research

Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling.
Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling. J Cancer Res Clin Oncol. 2014 Sep 11; Authors: Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D, Daniels B, Ward RL, Ford CE Abstract PURPOSE: Wnt signalling has been implicated in breast cancer, and in particular aberrant β-catenin-independent Wnt signalling has been associated with breast cancer metastasis and Tamoxifen resistance. Despite Wnt pathway involvement in many human cancers, attempts to target the pathway therapeutically have...
Source: Clinical Breast Cancer - September 11, 2014 Category: Cancer & Oncology Authors: Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D, Daniels B, Ward RL, Ford CE Tags: J Cancer Res Clin Oncol Source Type: research

Aberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancers.
In conclusion, our data indicated that the expression of LPA receptor 3 was increased in human TNBCs and is associated with tumor metastatic ability, and this implies that LPA3 is a potential therapeutic target for the treatment of TNBCs. PMID: 25209561 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 11, 2014 Category: Cancer & Oncology Authors: Sun K, Cai H, Duan X, Yang Y, Li M, Qu J, Zhang X, Wang J Tags: Clin Exp Med Source Type: research

Associations of the Fecal Microbiome With Urinary Estrogens and Estrogen Metabolites in Postmenopausal Women.
Conclusions: Our data suggest that women with a more diverse gut microbiome exhibit an elevated urinary ratio of hydroxylated estrogen metabolites to parent estrogen. Further research is warranted to confirm and relate these findings to clinical disease. PMID: 25211668 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 11, 2014 Category: Cancer & Oncology Authors: Fuhrman BJ, Spencer Feigelson H, Flores R, Gail MH, Xu X, Ravel J, Goedert JJ Tags: J Clin Endocrinol Metab Source Type: research

Diagnostic issues with significant tumour displacement in breast biopsies.
PMID: 25214055 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 11, 2014 Category: Cancer & Oncology Authors: Lightfoot N, Tawfik B, Fox SB Tags: J Clin Pathol Source Type: research

Treatment persistence evaluation of tamoxifen and aromatase inhibitors in breast cancer patients in early and late stage disease.
Conclusion: In conclusion, persistence with endocrine treatment in woman with hormone-receptor-positive breast cancer is low, especially in later stage disease, and needs to be significantly increased to improve outcome in clinical practice. Further research is required to understand this complex, but important aspect. PMID: 25207549 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 10, 2014 Category: Cancer & Oncology Authors: Schmidt N, Kostev K, Jockwig A, Kyvernitakis I, Albert US, Hadji P Tags: Int J Clin Pharmacol Ther Source Type: research

Breast cancer: Zoledronic acid-more than just a bone drug.
PMID: 25200411 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 9, 2014 Category: Cancer & Oncology Authors: Mathew A, Brufsky A Tags: Nat Rev Clin Oncol Source Type: research

siRNA-mediated silencing of CDK8 inhibits proliferation and growth in breast cancer cells.
CONCLUSIONS: CDK8 plays an essential role in breast cancer progression, which might inhibit the proliferation and migration in breast cancer cells. PMID: 24427329 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2014 Category: Cancer & Oncology Authors: Li XY, Luo QF, Wei CK, Li DF, Fang L Tags: Int J Clin Exp Pathol Source Type: research

Impact of polysomy 17 on HER2 testing of invasive breast cancer patients.
Abstract BACKGROUND: Current American Society of Clinical Oncology/College of American Pathologists guidelines define HER2-positive tumors as those with>6 HER2 genes per nucleus or those with HER2/CEP17 (chromosome 17) ratio>2.2. These guidelines are potentially contradictory in tumors with polysomy of chromosome 17. The current study was performed to determine the impact of polysomy 17 on the interpretation of HER2 testing of invasive breast carcinomas. METHODS: Chromosome 17 copies and HER2 gene status were identified by fluorescent in situ hybridization in 384 cases with invasive breast cancer, and t...
Source: Clinical Breast Cancer - September 8, 2014 Category: Cancer & Oncology Authors: Liu Y, Ma L, Liu D, Yang Z, Yang C, Hu Z, Chen W, Yang Z, Chen S, Zhang Z Tags: Int J Clin Exp Pathol Source Type: research

Expression of metabolism-related proteins in triple-negative breast cancer.
Abstract To investigate the dominant metabolic type of triple-negative breast cancer (TNBC) and evaluate its clinical implication through analysis of protein expression related to glycolysis, glutaminolysis, and mitochondrial oxidative phosphorylation. Tissue samples from 129 patients with TNBC who underwent mastectomy due to invasive breast cancer from 2000 to 2005 were prepared for tissue microarray. By immunohistochemical staining of the tissue microarrays, the markers of glycolysis-related proteins (Glut-1, CAIX, MCT4), glutaminolysis-related proteins (GLS1, GDH, ASCT2), and mitochondrial enzymes (ATP synthase...
Source: Clinical Breast Cancer - September 8, 2014 Category: Cancer & Oncology Authors: Kim MJ, Kim DH, Jung WH, Koo JS Tags: Int J Clin Exp Pathol Source Type: research

Evaluation of the progesterone receptor status in breast cancer using three different antibodies: a comparison by Allred score system.
In this study, we evaluated progesterone receptor (PR) expression in 53 BC cases using 3 anti-PgR antibodies (AB): monoclonal (SP42 and PgR636) and polyclonal ab62621. Primary BC cases (with signed informed consent) were used to generate tissue microarray platforms, where PR expression was accessed by IHC and evaluated by the Allred score. Categorical and quantitative data are shown in percentage and mean, respectively. Concordance (CON) and correlation among ABs were analyzed by Kappa factor (Κ), Spearman's correlation coefficient (ρ) or intraclass correlation coefficient. Staining patterns of each AB were compa...
Source: Clinical Breast Cancer - September 8, 2014 Category: Cancer & Oncology Authors: Daltoé RD, Madeira KP, de Carvalho AA, de Rezende LC, Silva IV, Rangel LB Tags: Int J Clin Exp Pathol Source Type: research

Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype.
CONCLUSION: Metachronous bilateral breast cancers, compared to synchronous bilateral breast cancers, are characterized by more aggressive phenotype, expressed by lower expression of estrogen receptor and stronger expression of cytokeratin 5/6 and vimentin; this does not, however, translate into differences in the distribution of intrinsic tumor phenotypes. PMID: 24427357 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2014 Category: Cancer & Oncology Authors: Senkus E, Szade J, Pieczyńska B, Zaczek A, Pikiel J, Sosińska-Mielcarek K, Karpińska A, Jassem J Tags: Int J Clin Exp Pathol Source Type: research

Eight-year experience with the intraoperative frozen section examination of sentinel lymph node biopsy for breast cancer in a North-Italian university center.
Abstract Sentinel lymph node biopsy (SLNB) completely changed the impact of breast surgery on patients psycho-physical wellness, reducing morbidity associated with complete axillary lymph node dissection (CALND) while granting an adequate breast cancer staging. We reviewed our experience with the SLNB in a University Clinic. We collected data about all breast cancer patients submitted to SLNB from 2002 to 2010, and analyzed them with R (version 2.15.2), considering significant p
Source: Clinical Breast Cancer - September 8, 2014 Category: Cancer & Oncology Authors: Cedolini C, Bertozzi S, Seriau L, Londero AP, Concina S, Cattin F, Geatti O, Di Loreto C, Risaliti A Tags: Int J Clin Exp Pathol Source Type: research

Primary thyroid T-lymphoblastic lymphoma: a case report and review of the literature.
Abstract Most thyroid lymphomas are B-lineage, and T-cell lymphomas are rare. Here, we report a case of primary T-cell lymphoblastic lymphoma (T-LBL) of the thyroid gland. A 15-year-old boy presented with a painless thyroid mass. Ultrasonographic examination revealed a hypoechoic thyroid nodule measuring 4.6 cm × 1.9 cm × 3.4 cm. The thyroid function and antibodies were normal. Hemithyroidectomy was performed. Intraoperative frozen section was suggestive of malignant lymphoma. Histological examination showed diffuse round to oval medium sized cells with high nuclear/cytoplasmic ratio, finely dispersed ...
Source: Clinical Breast Cancer - September 8, 2014 Category: Cancer & Oncology Authors: Chen C, Yang Y, Jin L, Dong L, Zhang X, Xiang Y Tags: Int J Clin Exp Pathol Source Type: research

Cutaneous necrosis as a result of isosulphane blue injection in mammarian sentinel lymph node mapping: report of two cases.
We present here two cases with cutaneous necrosis because of isosulphane blue injection after skin-sparing mastectomy and SLNB as a rare complication of dye injection. PMID: 25187747 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 8, 2014 Category: Cancer & Oncology Authors: Bircan HY, Ozcelik U, Koc B, Kemik O, Demirag A Tags: Clin Med Insights Case Rep Source Type: research

Autoantibodies in breast cancer.
un MC Abstract In addition to their historical role, autoantibodies appear promising as biomarkers to facilitate diagnosis, improve patient outcome and decrease mortality in cancer. Autoantibodies may also be useful in the identification of subjects at risk for cancer, that is, those bearing premalignant changes. Numerous studies have demonstrated that cancer serum contains a variety of autoantibodies that react with autologous cellular antigens, that is, tumor-associated antigens. Interestingly, some of these antigens are involved in signal transduction, cell cycle regulation, cell proliferation, and apoptosis. A...
Source: Clinical Breast Cancer - September 3, 2014 Category: Cancer & Oncology Authors: Fernández-Madrid F, Maroun MC Tags: Adv Clin Chem Source Type: research

Mammaglobin A: review and clinical utility.
Abstract Mammaglobin A is a protein that belongs to the secretoglobin superfamily. It has highly specific expression in cells from most breast cancers and may be used to detect circulating or disseminated tumor cells. In addition, mammaglobin A is currently under inves tigation as a potential therapeutic target for immune therapies that target breast cancer. The present review will highlight our current understanding of mammaglobin A at the genetic and protein level and its potential clinical applications. Characteristics of breast cancer and methods used to isolate and detect circulating tumor cells will also be ...
Source: Clinical Breast Cancer - September 3, 2014 Category: Cancer & Oncology Authors: Ghersevich S, Ceballos MP Tags: Adv Clin Chem Source Type: research

Thrombotic vasculopathy in a patient with initially undetected breast cancer.
PMID: 25160026 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 29, 2014 Category: Cancer & Oncology Authors: Emily BJ, Jonida C, Rachita B, Muhammad A, Thomas H Tags: J Clin Rheumatol Source Type: research

Comparison between invasive breast cancer with extensive peritumoral vascular invasion and inflammatory breast carcinoma: a clinicopathologic study of 161 cases.
Abstract OBJECTIVES: Extensive peritumoral neoplastic lymphovascular invasion (ePVI) is a marker of aggressiveness in invasive breast carcinoma (BC). METHODS: We explored the impact of ePVI on different BC subtypes. In a total of 2,116 BCs, 91 ePVI-BCs, 70 inflammatory breast carcinomas (IBCs), and 114 casual BCs as a control group (CG-BC) were recruited. RESULTS: Patients affected by ePVI-BC were younger, had larger tumors, higher histologic grade, elevated Ki-67 score, Her2/neu overexpressed, and more lymph node metastases compared with CG-BC (P
Source: Clinical Breast Cancer - August 18, 2014 Category: Cancer & Oncology Authors: Manfrin E, Remo A, Pancione M, Cannizzaro C, Falsirollo F, Pollini GP, Pellini F, Molino A, Brunelli M, Vendraminelli R, Ceccarelli M, Pagnotta SM, Simeone I, Bonetti F Tags: Am J Clin Pathol Source Type: research

Minimally invasive compared with conventional thyroidectomy for nodular goitre.
Abstract Since minimally invasive thyroidectomy was introduced in 1997, different surgical approaches to the thyroid have been described: the minimal neck incision and the anterior chest, areolar breast or axillary access. Whereas conventional open thyroidectomy is suitable for any thyroid disease, minimal neck incision thyroidectomy or extracervical scarless neck thyroidectomy are limited to small-volume disease. In 11 prospective randomized studies and six systematic reviews, minimally invasive video-assisted thyroidectomy via a central or lateral neck approach afforded better cosmesis in the first 3 months than...
Source: Clinical Breast Cancer - July 28, 2014 Category: Cancer & Oncology Authors: Dralle H, Machens A, Thanh PN Tags: Best Pract Res Clin Endocrinol Metab Source Type: research

Prognostic role of lemur tyrosine kinase 3 in postoperative gastric cancer.
Abstract The treatment of gastric cancer has been unsatisfactory thus far; therefore, novel targets and treatment strategies are urgently required. Lemur tyrosine kinase (LMTK)3 is an estrogen receptor-α (ERα) modulator with a central role in endocrine resistance in breast cancer. Moreover, the expression and polymorphisms of LMTK3 are correlated with the prognosis of breast cancer patients. Since estrogen receptor (ER) is also expressed and plays a role in gastric cancer, we herein investigated the expression of the LMTK3 protein in 83 gastric cancer patients by tissue microarray and analyzed the corr...
Source: Clinical Breast Cancer - July 28, 2014 Category: Cancer & Oncology Authors: Li Z, Wu J, Ji M, Shi L, Xu B, Jiang J, Wu C Tags: Mol Clin Oncol Source Type: research

Magnetic resonance imaging shrinkage patterns following neoadjuvant chemotherapy for breast carcinomas with an emphasis on the radiopathological correlations.
Abstract Preoperative neoadjuvant chemotherapy (NAC) is considered to be the standard treatment for locally-advanced breast carcinomas. Obtaining precise information regarding the tumor extent and distribution by imaging modalities to assess the success of breast-conserving surgery following NAC is extremely important. Analysis of the detailed radiopathological correlation of magnetic resonance imaging (MRI) following NAC has not been reported previously. The MRI and histopathological shrinkage patterns of residual breast carcinomas in 27 consecutive cases were analyzed following NAC and classified into five categ...
Source: Clinical Breast Cancer - July 28, 2014 Category: Cancer & Oncology Authors: Tomida K, Ishida M, Umeda T, Sakai S, Kawai Y, Mori T, Kubota Y, Mekata E, Naka S, Abe H, Okabe H, Tani T Tags: Mol Clin Oncol Source Type: research

Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients.
In conclusion, the association between TNBC and COX-2 overexpression in operable breast cancer supports further investigation into COX-2-targeted therapy for patients with TNBC. PMID: 25054056 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 28, 2014 Category: Cancer & Oncology Authors: Mosalpuria K, Hall C, Krishnamurthy S, Lodhi A, Hallman DM, Baraniuk MS, Bhattacharyya A, Lucci A Tags: Mol Clin Oncol Source Type: research

CYP2D6 Genotype and Adjuvant Tamoxifen.
Abstract A study by Province et al. for the International Tamoxifen Pharmacogenomics Consortium (ITPC) appeared in a recent issue of this journal.(1) In addition to discussing this study and biomarker studies in general, I provide an overall assessment of the evidence regarding testing for CYP2D6 in making clinical decisions regarding the use of tamoxifen in adjuvant breast cancer. PMID: 25056391 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 28, 2014 Category: Cancer & Oncology Authors: Berry DA Tags: Clin Pharmacol Ther Source Type: research

Interpreting the CYP2D6 Results From the International Tamoxifen Pharmacogenetics Consortium.
Abstract UNLABELLED: Meta-analysis of the entire analyzable cohort of 4,935 tamoxifen-treated breast cancer patients by the International Tamoxifen Pharmacogenetics Consortium (ITPC) (criterion 3) revealed no CYP2D6 effect on outcomes but strong heterogeneity across sites.(1) However, a post hoc-defined subgroup (criterion 1: postmenopausal, estrogen receptor positive, receiving 20 mg/day tamoxifen for 5 years; n = 1,996) did find a statistically significant effect of CYP2D6 on both invasive disease-free survival as well as breast cancer-free interval, with little site heterogeneity. How should we interpret...
Source: Clinical Breast Cancer - July 28, 2014 Category: Cancer & Oncology Authors: Province MA, Altman RB, Klein TE Tags: Clin Pharmacol Ther Source Type: research

An independent assessment of the 7 nomograms for predicting the probability of additional axillary nodal metastases after positive sentinel lymph node biopsy in a cohort of british patients with breast cancer.
CONCLUSION: The MOU nomogram was more predictive than the other nomograms, with a better AUC value and false-negative rate. None of the models were able to achieve AUC value ≥ 0.80 in a cohort of British patients with breast cancer. PMID: 25037530 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 22, 2014 Category: Cancer & Oncology Authors: Nadeem RM, Gudur LD, Saidan ZA Tags: Clin Breast Cancer Source Type: research

miR-296/Scribble axis is deregulated in human breast cancer and miR-296 restoration reduces tumour growth in vivo.
Abstract miR-296-5p is a central regulator of signalling pathways affecting development, stem cell differentiation and cancer. We hypothesized that miR-296-5p is involved in breast cancer onset and progression possibly through regulation of its target SCRIB (Scribble), a polarity protein recently implicated in the acquisition of cancer stem cell traits and in cell motility. We found that miR-296-5p levels were consistently reduced in human breast cancer tissues compared with non-neoplastic mammary parenchyma, and low expression of this miRNA predicted shorter disease-free survival independently of classic clinicop...
Source: Clinical Breast Cancer - June 22, 2014 Category: Cancer & Oncology Authors: Savi F, Forno I, Faversani A, Luciani A, Caldiera S, Gatti S, Foa P, Ricca D, Bulfamante G, Vaira V, Bosari S Tags: Clin Sci (Lond) Source Type: research

Oral Presentations.
In conclusion, a novel composite polymeric film was fabricated using simple electrochemical method and applied for determination of CPM in real samples. The sensor showed a good stability and sensitivity regardless the matrix of the pharmaceutical preparation. References 1. Rubinstein I, Bard A. J. J. Am. Chem. SOC. 1980;102;6641-6842. 2. Su M, Wei W, Liu S. Analytica Chimica Acta 2011;704:16-32. 3. Zhang B, Shi S, Shi W, Sun Z, Kong X, Wei M, Duan X. Electrochimica Acta 2012;67:133-139. O0006 Experimental Evidence of the Occurrence of an Intermolecular Electron Transfer in the Catalyzed Decomposition of spiro-Alkyl-1,2-Di...
Source: Clinical Breast Cancer - June 12, 2014 Category: Cancer & Oncology Tags: Luminescence Source Type: research

Epidemiology of Breast Cancer.
This article outlines the current incidence, prevalence, and mortality of breast cancer and reviews the epidemiology of the disease. Major risk factors for the development of breast cancer are covered, including reproductive, genetic, and environmental variables. Understanding the epidemiology of breast cancer will help clinicians identify high-risk patients for appropriate screening and informed disease management decisions. PMID: 24882341 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 7, 2014 Category: Cancer & Oncology Authors: Ban KA, Godellas CV Tags: Surg Oncol Clin N Am Source Type: research

Prophylactic Bilateral Mastectomy and Contralateral Prophylactic Mastectomy.
Abstract With increasing public awareness of the risk for breast cancer and modern techniques of reconstruction, the option of surgical prophylaxis for risk reduction is becoming increasingly popular. Bilateral prophylactic mastectomy for women at increased risk of developing breast cancer and contralateral prophylactic mastectomy for those with unilateral breast cancer seeking symmetry, risk reduction, and ease of follow-up are acceptable options for many women. However, prophylactic surgery is not an inconsequential decision, and careful consideration should be given to the risks and benefits of such procedures....
Source: Clinical Breast Cancer - June 7, 2014 Category: Cancer & Oncology Authors: Chagpar AB Tags: Surg Oncol Clin N Am Source Type: research

Applications for Breast Magnetic Resonance Imaging.
This article reviews the relevant data on breast magnetic resonance imaging (MRI) use in screening, the short-term surgical outcomes and long-term cancer outcomes associated with the use of MRI in breast cancer staging, the use of MRI in occult primary breast cancer, as well as MRI to assess eligibility for accelerated partial breast irradiation and to evaluate tumor response after neoadjuvant chemotherapy. MRI for screening is supported in specific high-risk populations, namely, women with BRCA1 or BRCA2 mutations, a family history suggesting a hereditary breast cancer syndrome, or a history of chest wall radiation. ...
Source: Clinical Breast Cancer - June 7, 2014 Category: Cancer & Oncology Authors: Pilewskie M, Morrow M Tags: Surg Oncol Clin N Am Source Type: research

Molecular Profiling of Breast Cancer.
This article addresses the importance and application of molecular subtype analysis, and provides an in-depth analysis of the clinical application of the molecular prognostic indices for ductal carcinoma in situ, node-negative invasive breast cancer, and node-positive invasive breast cancer. PMID: 24882344 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 7, 2014 Category: Cancer & Oncology Authors: Cyr AE, Margenthaler JA Tags: Surg Oncol Clin N Am Source Type: research

Management of the Clinically Node-Negative Axilla in Primary and Locally Recurrent Breast Cancer.
Abstract For patients with primary breast cancer, nodal status remains a key determinant for overall prognosis. Sentinel lymph node biopsy (SLNB) has become standard care for staging patients who have clinically node-negative disease. However, a new dilemma has arisen: how to manage the clinically negative axilla in patients with ipsilateral breast tumor recurrences (IBTRs). Are outcomes in these patients improved with repeat SLNB? Although observational studies suggest SLNB is feasible in patients with IBTR and a clinically node-negative axilla, the overall impact on morality and local recurrence is not yet known...
Source: Clinical Breast Cancer - June 7, 2014 Category: Cancer & Oncology Authors: McGinity AC, Lautner MA, Jatoi I Tags: Surg Oncol Clin N Am Source Type: research

Management of Axillary Disease.
Abstract The presence of nodal metastases is the most important prognostic indicator in breast cancer, making accurate assessment of the axillary nodal basin critical to delivering optimal therapy in breast cancer. Clinically node-negative women can be reliably staged in a minimally invasive manner using sentinel lymph node dissection (SLND). In node-negative patients receiving neoadjuvant chemotherapy, SLND can be performed after chemotherapy, allowing for a single surgical procedure and a decreased probability of requiring axillary lymph node dissection (ALND). Clinically node-positive patients are currently rec...
Source: Clinical Breast Cancer - June 7, 2014 Category: Cancer & Oncology Authors: Caudle AS, Cupp JA, Kuerer HM Tags: Surg Oncol Clin N Am Source Type: research

Lobular Neoplasia.
Abstract Lobular neoplasia (LN) is characterized by a dysfunctional E-cadherin-catenin axis, and loss of E-cadherin plays a causative role in the typical morphology of LN cells. LN is both a nonobligate precursor and a risk indicator of invasive breast cancer, and in particular, of invasive lobular carcinoma. Despite the evidence supporting the precursor role of LN, its impact on clinical management has been a matter of controversy, and conservative management remains the mainstay of treatment. In this article, an update is provided on the pathology and genetics of LN, and the management of these lesions in surgic...
Source: Clinical Breast Cancer - June 7, 2014 Category: Cancer & Oncology Authors: King TA, Reis-Filho JS Tags: Surg Oncol Clin N Am Source Type: research

Neoadjuvant Therapy in the Treatment of Breast Cancer.
Abstract Neoadjuvant systemic therapy in breast cancer treatment was initially utilized for inoperable disease. However, several randomized prospective studies have demonstrated comparable survival with adjuvant chemotherapy in early-stage, operable breast cancer while also decreasing tumor size facilitating breast conservation without significant increases in local recurrence. Response to therapy can predict outcome, with improved survival associated with pathologic complete response (pCR). Triple negative and HER2-positive subtypes show increased pCR rates. A multidisciplinary approach is necessary with neoadjuv...
Source: Clinical Breast Cancer - June 7, 2014 Category: Cancer & Oncology Authors: Teshome M, Hunt KK Tags: Surg Oncol Clin N Am Source Type: research

Advances in Breast Reconstruction of Mastectomy and Lumpectomy Defects.
Abstract Breast reconstruction continues to evolve along with advances in the detection and management of breast cancer. With more patients diagnosed with breast cancer earlier in life and increased identification of genetic mutations predisposing patients to breast cancer, patients' desires and expectations regarding reconstruction have become more sophisticated. Restoration of the breast to a form as close as possible to its presurgical state continues to be a primary goal. The past decade has seen many advances in implant and autologous tissue-based reconstruction. The future of reconstruction for breast cancer...
Source: Clinical Breast Cancer - June 7, 2014 Category: Cancer & Oncology Authors: Ballard TN, Momoh AO Tags: Surg Oncol Clin N Am Source Type: research

Nipple-Sparing Mastectomy: An Oncologic and Cosmetic Perspective.
Abstract The guiding principles of nipple-sparing mastectomy (complete removal of the breast from its skin and reconstructing without changing the appearance of the breast) are based on patient safety followed by oncologic safety. Recent advances have also taken into account cosmetic outcome. The ultimate in cosmetic outcome after mastectomy with reconstruction includes preservation of the nipple-areola complex, called a nipple-sparing mastectomy. The evidence-based transition and transformation to nipple-sparing mastectomy from both an oncologic standpoint and a cosmetic perspective are outlined in this article. ...
Source: Clinical Breast Cancer - June 7, 2014 Category: Cancer & Oncology Authors: Laronga C, Smith P Tags: Surg Oncol Clin N Am Source Type: research

Basal-Like and Triple-Negative Breast Cancers: Searching for Positives Among Many Negatives.
Abstract Triple-negative breast cancers (TNBC) are defined by their failure to express the estrogen receptor, progesterone receptor, and HER2/neu protein markers. This basic feature is clinically relevant because it indicates that these cancers cannot be managed with endocrine or anti-HER2 systemic therapies. Furthermore, most TNBC cases are also characterized as being of the genetically defined basal subtype, which is an inherently and biologically more aggressive pattern of disease. The two terms, however, are not synonymous, and some TNBC cases are prognostically more favorable. TNBC differs from non-TNBC in ri...
Source: Clinical Breast Cancer - June 7, 2014 Category: Cancer & Oncology Authors: Alluri P, Newman LA Tags: Surg Oncol Clin N Am Source Type: research

Breast Cancer Disparities: High-Risk Breast Cancer and African Ancestry.
Abstract African American women have a lower lifetime incidence of breast cancer than white/Caucasian Americans yet have a higher risk of breast cancer mortality. African American women are also more likely to be diagnosed with breast cancer at young ages, and they have higher risk for the biologically more aggressive triple-negative breast cancers. These features are also more common among women from western, sub-Saharan Africa who share ancestry with African Americans, and this prompts questions regarding an association between African ancestry and inherited susceptibility for certain patterns of mammary carcino...
Source: Clinical Breast Cancer - June 7, 2014 Category: Cancer & Oncology Authors: Newman LA Tags: Surg Oncol Clin N Am Source Type: research

Nonsurgical Ablation of Breast Cancer: Future Options for Small Breast Tumors.
Abstract The surgical management of breast cancer has evolved significantly, facilitated by advancements in technology and imaging and improvements in adjuvant therapy. The changes in surgical management have been characterized by equal or improved outcomes with significantly less morbidity. The next step in this evolution is the minimally invasive or noninvasive ablation of breast cancers as an alternative to lumpectomy. In this article, the various modalities for nonsurgical breast cancer ablation and the clinical experience are reviewed, and some of the next steps necessary for their clinical implementation are...
Source: Clinical Breast Cancer - June 7, 2014 Category: Cancer & Oncology Authors: Sabel MS Tags: Surg Oncol Clin N Am Source Type: research